Equities

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)39.18
  • Today's Change-0.19 / -0.48%
  • Shares traded5.40m
  • 1 Year change-28.88%
  • Beta1.0659
Data delayed at least 15 minutes, as of Sep 30 2022 08:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.

  • Revenue in CNY (TTM)5.15bn
  • Net income in CNY827.13m
  • Incorporated1998
  • Employees4.08k
  • Location
    Zhejiang Jiuzhou Pharmaceutical Co LtdNo.99, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
  • Phone+86 57 688706789
  • Fax+86 57 688706788
  • Websitehttp://www.jiuzhoupharma.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
603456:SHH since
announced
Transaction
value
Nanjing Kangchuanji Medicine Technology Co LtdAnnounced04 Jan 202204 Jan 2022Announced-30.36%18.89m
Teva Pharmaceutical & Chemical (Hangzhou) Co LtdDeal completed24 Nov 202124 Nov 2021Deal completed-26.83%34.00m
Data delayed at least 15 minutes, as of Sep 30 2022 08:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fujian Kuncai Material Technology Co Ltd843.16m113.93m27.81bn729.00244.0715.72--32.980.24350.24351.803.780.27620.96684.841,156,599.003.888.735.0410.3631.9841.2514.0322.780.44256.850.435710.4319.1016.95-8.475.7425.27--
Hunan Changyuan Lico Co Ltd11.63bn1.14bn28.65bn1.50k17.474.05--2.460.84990.84997.303.671.195.894.247,734,855.0011.72--20.96--16.42--9.85--1.23--0.2768--240.25--538.17------
Suzhou Nanomicro Technology Co Ltd574.56m288.10m29.11bn536.0093.6120.85--50.660.77130.77131.523.460.41090.8194.971,071,937.0020.74--22.90--82.22--50.47--4.09--0.101--117.74--158.75------
Sichuan Hebang Biotechnology Co Ltd13.43bn4.74bn29.14bn4.92k5.841.65--2.170.56550.56551.602.000.71028.1616.472,730,898.0025.176.1131.177.4246.6528.2135.4413.641.92319.490.077718.5587.5623.307,284.2856.9120.6926.95
Zhejiang Longsheng Group Co., Ltd17.32bn2.27bn29.70bn7.80k13.040.9534--1.710.70020.70025.339.580.25010.44465.602,220,434.003.877.876.9311.6429.3739.7915.4723.240.57977.190.423921.166.766.16-19.2110.718.654.56
Zhejiang Jiuzhou Pharmaceutical Co Ltd5.15bn827.13m30.18bn4.08k36.586.19--5.860.98890.98896.165.850.73062.176.181,261,216.0011.747.3517.179.6034.2733.5016.0612.621.06--0.20450.0153.4819.7066.5641.5731.8635.09
Meihua Holdings Group Co Ltd26.03bn3.92bn30.27bn12.95k7.882.57--1.161.261.268.403.871.196.3462.802,009,729.0018.047.0625.8410.2723.1420.5315.118.441.04--0.348877.2133.9415.54139.4017.6823.755.92
Jiangsu Yangnong Chemical Co.,Ltd.14.72bn1.95bn30.99bn3.12k15.933.75--2.106.286.2847.5126.681.026.724.524,722,367.0013.5211.0224.1919.7925.4826.0313.2112.071.16--0.320620.3120.4532.231.0222.7118.858.61
XTC New Energy Materials Xiamen Co Ltd23.30bn836.85m31.32bn1.97k31.326.33--1.343.333.3392.6216.452.248.087.3711,851,450.008.14--19.01--9.02--3.64--0.79318.960.5573--94.82--121.66------
Skshu Paint Co Ltd11.45bn-434.05m32.26bn10.34k--15.84--2.82-1.16-1.1630.495.410.922610.872.731,107,682.00-3.523.55-10.889.5426.3533.09-3.813.020.7346-5.160.722945.0039.3742.45-183.08--63.86--
Data as of Sep 30 2022. Currency figures normalised to Zhejiang Jiuzhou Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

22.90%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 31 Dec 202155.72m6.71%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 202144.20m5.32%
China Universal Asset Management Co., Ltd.as of 31 Dec 202129.50m3.55%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 202112.27m1.48%
China Southern Asset Management Co., Ltd.as of 31 Dec 20219.22m1.11%
China Fund Management Co., Ltd.as of 31 Dec 20219.22m1.11%
GF Fund Management Co., Ltd.as of 31 Dec 20218.59m1.04%
AXA-SPDB Investment Managers Co., Ltd.as of 31 Dec 20217.48m0.90%
Harvest Fund Management Co., Ltd.as of 31 Mar 20217.14m0.86%
Changjiang Pension Insurance Co. Ltd.as of 09 Aug 20216.75m0.81%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.